Prostate Cancer | Specialty

Dr. Graff on Results of the KEYNOTE-199 Trial in mCRPC

February 27th 2020

Julie N. Graff, MD, discusses the results of the phase II KEYNOTE-199 trial in metastatic castration-resistant prostate cancer.

Dr. Oh on Remaining Challenges With Prostate Cancer Treatment

February 27th 2020

William K. Oh, MD, discusses remaining challenges with the advancing treatments in prostate cancer.

Dr. Grivas on Comparisons Between ATM and BRCA1/2 Mutations in mCRPC

February 27th 2020

Petros Grivas, MD, discusses comparisons between ATM and BRCA1/2 mutations in metastatic castration-resistant prostate cancer.

Researchers Building on Darolutamide Success in Prostate Cancer

February 26th 2020

Martin T. King, MD, PhD, discusses the INTREPId trial exploring darolutamide plus radiation therapy in patients with prostate cancer.

Neoadjuvant and Adjuvant ADT With Dose-Escalated PRT Show Similar Outcomes in Prostate Cancer

February 26th 2020

Neoadjuvant and concurrent androgen-deprivation therapy (ADT) with dose-escalated prostate radiotherapy (PRT) and concurrent and adjuvant ADT plus dose-escalated PRT were found to have no statistically significant differences in biochemical relapse-free survival in patients with localized prostate cancer, according to results of a phase III trial.

Dr. Tagawa on Preliminary Data With 225Ac-J591 in mCRPC

February 25th 2020

Scott T. Tagawa, MD, MS, discusses preliminary data with 225Ac-J591 in metastatic castration-resistant prostate cancer.

Dr. Armstrong on the Rationale of the PROPHECY Trial in mCRPC

February 21st 2020

Andrew J. Armstrong, MD, discusses the rationale of the PROPHECY trial in metastatic castration-resistant prostate cancer.

Dr. Tan on the Risk of Novel Coronavirus for Patients With Cancer

February 21st 2020

Christina Tan, MD, MPH, discusses the potential impact of the novel coronavirus on patients with cancer.

Dr. Fendler on Clinical Need for 68GA-PSMA-11 PET in Prostate Cancer

February 21st 2020

Wolfgang Fendler, MD, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, discusses the clinical need for 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer.

Dr. Graff on the KEYNOTE-199 Trial Design in Castration-Resistant Prostate Cancer

February 20th 2020

Julie N. Graff, MD, discusses the multi-cohort, phase II KEYNOTE-199 study examining patients with metastatic castration-resistant prostate cancer.

Increased Genetic Screening May Lead to Earlier Prostate Cancer Diagnoses

February 19th 2020

William L. Dahut, MD, discusses the natural history trial, the implications of the PROfound study, and the importance of screening for men at a high risk for developing prostate cancer.

Cabozantinib Plus Atezolizumab Active in mCRPC

February 19th 2020

The combination of cabozantinib and atezolizumab demonstrated clinically meaningful activity in patients with metastatic castration-resistant prostate cancer, including those with high-risk clinical features.

Dr. Pal on the Rationale for Adding Cabozantinib to Atezolizumab in Prostate Cancer

February 19th 2020

Sumanta K. Pal, MD, discusses the rationale for adding cabozantinib to atezolizumab in prostate cancer.

Dr. Freedland on a Real-World Analysis of Enzalutamide in mCRPC

February 19th 2020

Stephen J. Freedland, MD, discusses a real-world analysis of enzalutamide in metastatic castration-resistant prostate cancer.

Breaking Ground in GU Cancers

February 17th 2020

Daniel P. Petrylak, MD, discusses important new developments in bladder and prostate cancer.

Dr. Antonarakis on Sipuleucel-T Plus Radium-223 in Bone-Metastatic CRPC

February 15th 2020

Emmanuel S. Antonarakis, MBBCh, professor of oncology, Johns Hopkins Medicine, discusses a phase II trial evaluating the combination of sipuleucel-T (Provenge) plus radium-223 dichloride (Xofigo) versus sipuleucel-T alone in patients with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC).

Dr. Vargas on Determining Role of SBRT Oligometastatic Prostate Cancer

February 15th 2020

Carlos E. Vargas, MD, examines the use of stereotactic body radiation therapy (SBRT) in oligometastatic prostate cancer.

ASCO GU 2020: Dr. Rini Highlights Key Research Efforts in Kidney Cancer

February 14th 2020

ASCO GU 2020: Dr. Petrylak Discusses Exciting Prostate Cancer and Bladder Cancer Data

February 14th 2020

ASCO GU 2020: Dr. Taplin Highlights Ongoing Research in Prostate Cancer

February 14th 2020